All In MedTech

Device Trial Radar · NCT06071429

Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease

Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Apr 11, 2025

Primary completion

Mar 1, 2028

Study completion Mar 1, 2032

Sponsor

Lead sponsor
R3 Vascular Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 6, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this prospective, single-blinded, randomized controlled trial is to evaluate the safety and efficacy of the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Approximately 276 subjects will be randomized in a 1:1 ratio. The clinical investigation will be conducted at up to 60 clinical sites globally.

Conditions

  • Chronic Limb-Threatening Ischemia

Interventions

  • MAGNITUDE Sirolimus-eluting Bioresorbable ScaffoldDevice

    CLTI patients treated with MAGNITUDE BRS

  • Percutaneous Transluminal Angioplasty (PTA)Device

    CLTI patients treated with PTA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety Endpoint: Freedom from MALE+POD (Major Adverse Limb Event + Peri-Operative Death)Time frame: POD at 30 Days and MALE at 6 months

1 more outcomes with a free account

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York · Recruiting

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.